IPA's LENS ai ™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENS ai ™ platform, with a direct comparison to gold-standard wet-lab methods.
LENSai's AI-powered platform was able to match the performance of x-ray crystallography—the industry's most precise but slowest and most expensive method—using sequence data alone
The results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. LENS ai 's AI-powered platform was able to match the performance of x-ray crystallography—the industry's most precise but slowest and most expensive method—using sequence data alone.
"In an industry where over 95% of drug candidates fail before reaching the clinic, accelerating decisions earlier in the discovery pipeline isn't a luxury—it's a necessity," said Dr. Jennifer Bath, CEO of IPA. "With LENS ai, we're demonstrating that AI is designed to deliver accurate, scalable, and human-relevant biological predictions that were previously only accessible through months of experimental work."
In the benchmarking study, LENS ai 's in silico epitope mapping application was tested across five known antibody-antigen pairs and against multiple experimental techniques, including HDX-MS, alanine scanning, and x-ray crystallography. The AI system produced predictive scores (AUC 0.79–0.89) comparable to or exceeding those achieved by leading wet-lab methods, while reducing turnaround time from weeks to hours.
Epitope mapping is a cornerstone of antibody development, informing everything from IP strategy to candidate selection. Traditionally, this requires expensive, time-consuming lab work using scarce protein samples. LENS ai transforms this by delivering early-stage epitope insights from sequence alone, reducing both cost and risk.
This breakthrough aligns with growing regulatory and industry momentum around New Approach Methodologies (NAMs), including the FDA's recent decision to phase out animal testing requirements for biologics. By eliminating the need for physical materials and enabling near–x-ray-level precision, LENS ai advances ethical, scalable, and high-resolution approaches to biotherapeutic discovery
We view this achievement as a meaningful advancement that enhances the capabilities of drug discovery platforms" added Dr. Bath. "LENS ai is now capable of providing pharma and biotech partners with validated, in silico answers to questions that once required months of wet-lab commitment."
This latest achievement marks a major step in the broader development of LENS ai, IPA's AI-driven discovery platform. Building on previous releases, including in silico antibody engineering, epitope prediction, and multi-omics integration, LENS ai continues to demonstrate its ability to deliver high-resolution, scalable insights across key stages of biotherapeutic discovery. Today's advancement in epitope mapping reflects the growing power of the platform we have been strategically building — connecting sequence-based precision, accelerated timelines, and deep scientific insight to transform the future of therapeutic development.
To read the full case study: LENSai Epitope Mapping Matches X-ray Crystallography
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family').
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements often include words such as "expects," "intends," "anticipates," "believes," or variations thereof, or state that certain actions, events, or results "may," "will," "could," or "might" occur. These statements relate to, among other things, the anticipated benefits, scalability, and adoption of the LENSai platform, the broader application of HYFT®-based tools, the advancement of AI-native drug discovery methods, and the Company's ability to maintain regulatory alignment and commercial traction.
Although the Company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to factors largely beyond the Company's control, including but not limited to scientific and technological developments, regulatory changes and acceptance, competitive dynamics, IP protection, platform integration challenges, and financial and operational risks.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information on risks and uncertainties can be found in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should any of these risks materialize, actual results could vary significantly.
Readers are cautioned not to place undue reliance on forward-looking statements, which reflect the Company's expectations only as of the date of this release. The Company assumes no obligation to update or revise these statements, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
HEALWELL AI Leverages Orion Health to Power Entry into US Market
HEALWELL launches in the U.S. market a suite of AI enabled tools to complement Orion Health's established software offerings in the U.S. This will bring together HEALWELLs globally validated AI capabilities with Orion Health's best-in-class health data infrastructure software creating a unique offering for the U.S. market. This U.S. market launch leverages Orion Health's deep U.S. sector experience, existing U.S. footprint and multi-decade track record of delivering health data infrastructure software to customers in eight U.S. states. US digital-health market spend reached $160.4 billion in 2024 and is forecast to grow at a 15.4% CAGR from 2025 to 2033 to reach $695.2 billion by 20331. As the U.S. healthcare sector is the largest globally; HEALWELL views the U.S. market as a key jurisdiction of focus. Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce a strategic expansion into the U.S. healthcare market, aligning the group's direction following its acquisition of Orion Health. This move marks a major milestone in HEALWELL's mission to advance preventative care through AI-driven insights and trusted health data infrastructure. With over two decades of experience in the U.S, Orion Health has built a strong foundation supporting health information exchanges (HIEs), accountable care organizations (ACOs), clinically integrated networks (CINs), payers, and health systems. Its technology powers clinical data exchange across eight states, enabling thousands of clinicians to access health information for millions of patients, every day. This embedded presence will give HEALWELL immediate reach and credibility in one of the world's largest and most complex healthcare environments. To support this strategic expansion, HEALWELL has established dedicated U.S. and Canadian teams, reflecting the distinct regulatory, funding, and market dynamics of each region. "Orion has had a material presence in the USA for over two decades," said Brad Porter, Chief Commercial Officer at HEALWELL. "We now have a unique opportunity to accelerate value for our customers by combining Orion's trusted platform with HEALWELL's next-generation AI capabilities. The robust clinical validation and data lineage features differentiates these tools in the market and ultimately reduces friction with regards to clinical adoption." HEALWELL's U.S. strategy will focus on the delivery of value-based care and population health initiatives through two critical capabilities: health data infrastructure and a suite of AI-enabled tools to be made available as a compelling offering to ACOs, CINs, HIEs, payers and health systems. As regulatory frameworks like TEFCA along with convergence of standards towards FHIR reshape the national data landscape, HEALWELL is introducing a modular, FHIR-native repository to work alongside Orion's robust HL7-based data repository. This approach enables a TEFCA-ready, standards-aligned architecture that supports longitudinal patient records, interoperability, and real-time data sharing, while providing a clear upgrade path for existing HIEs and provider networks. Complementing this foundation is HEALWELL's growing suite of AI tools which will be introduced to the market, including AI-enabled clinical search, AI-enabled clinical summarisation and AI-enabled patient identification and risk stratification. These tools are designed to integrate seamlessly into existing clinical infrastructure, helping care teams surface insights faster, reduce administrative burden, and improve clinical outcomes. "The demand for clinically validated and explainable AI is growing fast," said Dr. Alexander Dobranowski, CEO of HEALWELL. "Our ability to embed these tools into existing systems rather than replace them means we can drive impact quickly, without disrupting workflows." To deepen its U.S. market presence, HEALWELL will also focus on strategic partnerships and M&A. Dr. Dobranowski adds, "As highlighted by our track record, we will be continuing to evaluate U.S. oriented partnerships, acquisition opportunities and organic expansion to ensure capital allocation matches the ambition of HEALWELLs purpose of enabling the adoption of AI driven preventative care." Beyond providers and public health systems, HEALWELL also sees growing demand from the life sciences sector, where real-world evidence (RWE) generation, decentralized clinical trial orchestration, and identifying gaps in patient care are increasingly common. With established life sciences partnerships and a platform built for scalability, HEALWELL is well-positioned to support clinical research, clinical development, and outcomes-based engagement in the U.S. market. HEALWELL's subsidiaries Pentavere and Khure Health have an established track record with U.S. life sciences and health system organizations and are currently commercially active with 7 of the top 10 largest pharmaceutical companies globally. "We're seeing real traction and a path to significant growth," said James Lee, incoming CEO of HEALWELL. "We're making excellent progress on integration and go-to-market plans, and we're seeing significant opportunities to both expand responsibly and rationalize expenses to improve operating margins. We're at the start of the curve in proving how AI can improve patient outcomes and help healthcare systems become more targeted with their resources. It's an exciting time for the industry." HEALWELL's U.S. oriented portfolio of capabilities will include HEALWELL Data as a Service, a FHIR complaint data store and a growing suite of AI-enabled tools that support clinical search, patient clinical summarisation, patient identification and patient risk stratification. These capabilities complement Orion Health's established and scaled U.S. offerings, including Amadeus Digital Care Record, Virtuoso Digital Front Door, and Communicate Direct Secure Messaging, creating an integrated platform that will deliver both infrastructure and intelligence to the frontlines of care. Dr. Alexander DobranowskiChief Executive OfficerHEALWELL AI Inc. 1 About HEALWELL HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTCQX Market under the symbol "HWAIF". To learn more about HEALWELL, please visit Forward-Looking Statements Certain statements in this press release, constitute "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including statements about the potential for HEALWELL and Orion Health to develop new products and services, or to enhance or combine existing ones, and the anticipated impact of such products and services; and the anticipated timing, focus and implementation of Healwell's strategic expansion into the U.S. Market; and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as "mission", "opportunity", "introducing", "is engaging", "continue to", "improve" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward-looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: HEALWELL's ability to integrate Orion Health personnel, products, services, customers and relationships; HEALWELL's and Orion Health's ability to maintain and leverage their relationships with their commercial partners; the continued adoption of the software, tools and solutions created by HEALWELL and its subsidiaries; that HEALWELL will be successful in identifying, executing and integrating new acquisitions, investments and/or partnerships, the stability of general economic and market conditions; sufficiency of working capital and access to financing; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; technologies working as intended or at all; trends in customer growth and the adoption of new technologies in the industry; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated March 31, 2025, which is available under HEALWELL's SEDAR+ profile at The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements. For more information: Pardeep S. SanghaInvestor Relations, HEALWELL AI 604-572-6392ir@ To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
Huawei Unveils Fully-Upgraded Xinghe Intelligent Network Offerings to Accelerate Digital and Intelligent Transformation in Asia Pacific
HONG KONG, June 11, 2025 /PRNewswire/ -- At Huawei Network Summit 2025 (Asia Pacific), Huawei unveiled fully-upgraded Xinghe Intelligent Network products and solutions for the Asia Pacific region, and released the Technical Requirements for Financial Data Center Networks with the Network Innovation and Development Alliance (NIDA). All of these announcements will inject new vitality into digital and intelligent development in Asia Pacific. In the opening speech, Spawn Fan, President of Huawei's Asia Pacific Enterprise Sales Department, pointed out that AI development has far exceeded expectations, with record-breaking growth in AI users and adoption rates. Huawei responds to this by leveraging its unique full-stack capabilities and collaborating with partners to help customers in all industries build advanced infrastructure for the AI era. Mr. Sword Cheng, Vice President of Huawei's Data Communication Product Line, said in the speech that global industries are actively promoting the convergence of AI and network technologies. However, most solutions are still in the early stages of "network management + AI". As such, only end-to-end AI-powered networks are viable solutions in the AI era. Huawei's Xinghe Intelligent Network Solution is ideal for AI-powered networks through innovations in diverse domains. Xinghe Intelligent Campus leverages Wi-Fi Channel State Information (CSI) sensing technology to detect intrusions and identify unauthorized cameras in seconds through Wi-Fi signals, ensuring campus space security and privacy protection. Xinghe Intelligent Fabric provides intelligent assurance for general-purpose computing and intelligent computing scenarios. Xinghe Intelligent WAN employs an AI latency compensation algorithm to reduce the two-way latency variation to 3 μs, which is a 20-fold improvement over SDH networks. It also draws on AI algorithms to achieve a 95% identification rate of encrypted traffic, helping Internet Service Providers (ISPs) reduce latency by more than 65% and increase revenue by 20%. Xinghe Intelligent Network Security builds on an AI detection engine to achieve a 95% unknown malware identification rate. It also leverages a high-performance graph database to trace up to 100 hops back to the source. All of these help detect threats at a high accuracy and prevent virus spread. Huawei also announced a full lineup of all-new Xinghe Intelligent Network products and solutions for Asia Pacific. Examples include the industry's first 5-radio Wi-Fi 7 AP, unique "3S (spanning, stable, and secure)" StarryLink optical modules, the industry's highest-density 400GE full-service router, and differentiated solutions across industries. Huawei and NIDA jointly released the Technical Requirements for Financial Data Center Networks, which systematically defines key technical indicators of financial data center networks for the first time, serving as an industry-recognized network construction guide for financial institutions. Looking ahead, Huawei will further deepen AI-powered Xinghe Intelligent Network innovation and collaborate with Asia-Pacific customers across industries to accelerate intelligent transformation, explore new use cases, and stride to the digital and intelligent future together. View original content to download multimedia: SOURCE Huawei
Yahoo
25 minutes ago
- Yahoo
Capita to roll out AI-powered recruitment this summer
LONDON (Reuters) -Capita, a British outsourcer that works with government, armed forces and companies, said it was using AI to cut recruitment from weeks to just hours, and it would roll out the service, developed with Salesforce Inc, this summer. "We hire about 10,000 people for multiple operations and multiple contracts every year because of the nature of the transient workforce in some of our markets," Chief Executive Adolfo Hernandez said in an interview. Salesforce said Capita was the first business-to-business company in Britain to deploy its Agentforce AI, using it to automate more than 200 tasks, including recruitment, where it speeds up hiring from job specification to shortlisting. Hernandez said the tool, built in the first three months of the year, could produce a qualified pipeline of candidates that had been matched to the job, leaving recruiters more time to dedicate to final interviews and bringing new staff onboard. "We're going to tune it and then when we've got it ready, we'll go to market," he said. "High volume recruitment will probably be going to market this summer." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
